Chiltern sets up in Taiwan

By Natalie Morrison

- Last updated on GMT

Related tags Clinical trial Contract research organization

Chiltern sets up in Taiwan
Chiltern has set up a legal entity in Taiwan that will allow it to establish its own local clinical research operations for the first time.

The firm has so far been working within the area through CRO (contract research organisation) partners, but in the face of “client demand” ​has decided to take a more active role in the country.

“The legal entity is a local operating company, registered in Taiwan, that will give us the means to employ staff and carry out operations in Taiwan,”​ Owen Lewis, Chiltern’s executive VP of legal affairs, and general counsel told Outsourcing-Pharma.

The company is now hunting for staff in the area to start work on Phase II to IV global clinical trials as soon as possible.

Umakanta Sahoo, executive director of Asia Pacific and managing director of India – who is in charge of the expansion– told us that clients are pushing to work in the country because Asia is an attractive market, and Taiwan has an especially “supportive regulatory environment, excellent hospital infrastructure and healthcare system.”

He said: “Taiwan is a good country to perform clinical research and has other related opportunities Chiltern is pursuing.”

Sahoo added that existing regional collaborations between Chiltern’s units in Asian countries with the USA and European had whetted customers’ appetites for work within Taiwan.

Of partnering with local companies over research, Sahoo was coy, saying: “This depends on the nature of trials.”

He added: “We may work with local vendors or laboratories if the trial would require this.”

Venturing further into Asia-Pacific

Chiltern’s love affair with the Asia-Pacific​ region started with a drive for expansion in the region in 2010.

At the time spokeswoman Natalie Chong told Outsourcing-Pharma the business would focus on establishing more activities, with its Singapore unit acting as a central hub, adding: “The size of the clinical trial population coupled with the expanding network of investigators in key therapeutic areas of interest to Chiltern makes expansion in this region an essential choice.”

In last week’s statement about the new Taiwanese legal entity, Sahoo said more legal entities in other important countries will be a “natural progression”​ to strengthen Chiltern’s foothold.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars